MWNA
BIO icon

Marshall Wace North America’s Bio-Rad Laboratories Class A BIO Stock Holding History

Marshall Wace North America’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$5.19M Sell
6,953
-9,918
-59% -$7.43M 0.02% 497
2021
Q2 		$10.9M Sell
16,871
-7,579
-31% -$4.61M 0.05% 356
2021
Q1 		$14M Buy
24,450
+14,311
+141% +$8.47M 0.06% 335
2020
Q4 		$5.91M Buy
+10,139
New +$5.77M 0.03% 508
2020
Q3 		– Sell
-1,631
Closed -$736K – 1215
2020
Q2 		$736K Sell
1,631
-97
-6% -$42.8K ﹤0.01% 847
2020
Q1 		$605K Buy
+1,728
New +$635K ﹤0.01% 718
2019
Q4 		– Sell
-12,109
Closed -$4.03M – 1294
2019
Q3 		$4.03M Buy
+12,109
New +$3.95M 0.02% 401
2019
Q2 		– Sell
-1,933
Closed -$591K – 1173
2019
Q1 		$591K Buy
1,933
+232
+14% +$62.6K ﹤0.01% 764
2018
Q4 		$395K Buy
1,701
+889
+109% +$239K ﹤0.01% 825
2018
Q3 		$255K Sell
812
-2,081
-72% -$646K ﹤0.01% 814
2018
Q2 		$835K Sell
2,893
-1,895
-40% -$523K ﹤0.01% 977
2018
Q1 		$1.2M Buy
4,788
+2,922
+157% +$744K 0.01% 946
2017
Q4 		$445K Sell
1,866
-8,685
-82% -$2.1M ﹤0.01% 1166
2017
Q3 		$2.34M Buy
+10,551
New +$2.37M 0.01% 756
2017
Q2 		– Sell
-1,947
Closed -$387K – 1295
2017
Q1 		$387K Buy
+1,947
New +$375K ﹤0.01% 843

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Marshall Wace North America's BIO Position: Q3 2021 in Review

Marshall Wace North America reduced its Bio-Rad Laboratories Class A (BIO) stake by 59% in Q3 2021, selling an estimated $7.43M and leaving 6,953 shares worth $5.19M. The position accounts for 0.02% of the portfolio, ranked #497.

Marshall Wace North America first reported a position in BIO in Q1 2017 and has held it in 15 quarters since. The position peaked at $14M in Q1 2021. 508 funds tracked by Wall St. Rank hold BIO as of Q3 2021.

  • Marshall Wace North America held 6,953 shares of Bio-Rad Laboratories Class A worth $5.19M as of Q3 2021.
  • Marshall Wace North America sold 9,918 Bio-Rad Laboratories Class A shares in Q3 2021, an estimated $7.43M.
  • Bio-Rad Laboratories Class A made up 0.02% of Marshall Wace North America's portfolio in Q3 2021, its #497 holding.
  • Marshall Wace North America first reported a position in Bio-Rad Laboratories Class A in Q1 2017 and has held it in 15 quarters since.
  • Marshall Wace North America's Bio-Rad Laboratories Class A position peaked at $14M in Q1 2021.
  • 508 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.